Daewoong Pharma대웅제약
069620 · KOSPI · ₩069620 · 대웅제약
₩99,900▲ ₩800 (0.81%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 52.3% | 52.4% | 51.6% | 50.0% | 49.9% | 47.2% |
| Operating margin | 11.7% | 12.5% | 10.4% | 8.9% | 7.5% | 7.7% |
| Net margin | 12.0% | 12.5% | 1.7% | 8.9% | 3.3% | 2.1% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +4.1% | +10.4% | +3.4% | +7.4% | +11.0% | — |
| Operating income growth | −3.2% | +33.0% | +20.7% | +28.0% | +7.8% | — |
| Net income growth | −0.2% | +691.8% | −79.7% | +188.2% | +71.3% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 18.9% | 21.8% | 3.2% | 17.7% | 7.1% | 4.3% |
| Return on assets | 7.3% | 8.9% | 1.2% | 7.2% | 2.6% | 2.1% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 113.0% | 108.2% | 113.3% | 94.1% | 110.9% | 101.5% |
| Net debt to equity | 20.0% | 57.7% | 57.1% | 32.8% | 41.5% | 51.5% |
| Current ratio | 88.5% | 124.4% | 97.4% | 86.2% | 116.1% | 113.9% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Daewoong Pharma / 대웅제약 / 069620 / KRX:069620
Source: KRX statistical information